Abstract: The present invention relates to compositions with enhanced UV screening properties and methods of making same, and specifically, UV screening compositions including UV filters and silica boosters. The compositions consist of any suitable cosmetically acceptable carrier, one or more organic or inorganic UV filters and spherical silica. The present invention also discloses methods of making UV-screening compositions including spherical silica, wherein the methods comprise adding spherical silica during the process of combining the cosmetically acceptable carrier and UV filters or after the cosmetically acceptable carrier and UV filters have been combined.

Abstract: The present invention is in the field of hair treatment compositions; in particular relates to a method for hair volume reduction. Despite the prior art, there still exists the opportunity to increase the conditioning benefits delivered through hair treatment compositions. It is therefore an object of the present invention to provide a method that retains shape and reduces frizz even after exposure to humidity and washing the hair. It has been found that reduced hair frizz and hair shape retention even after exposure to moisture can be obtained by using N-formyl amino acids.

Abstract: The invention relates to a shampoo composition for enhancing deposition of oil drop onto a substrate, comprising a mixture of sulfonated methyl ester compounds containing two or more sulfonated methyl esters of a fatty acid having a chain length of 12 to 20 carbon atoms (C12-C20); a zwitterionic surfactant; an oil phase; and a cationic polymer. The shampoo composition may further comprise an inorganic electrolyte such as sodium chloride. The invention also relates to use of the shampoo composition for enhancing deposition of oil drop onto a substrate, wherein the composition comprises a specific blend of sulfonated methyl ester compounds.

Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

Abstract: The present invention has an object to provide a skin anti-aging agent, an agent for regulating expression of anti-aging related gene, and a cosmetic product comprising the anti-aging agent or the agent for regulating expression of anti-aging related gene which are very safe and can be used reliably for a long term. The skin anti-aging agent, the agent for regulating expression of anti-aging related gene, and the cosmetic product comprising the anti-aging agent or the agent for regulating expression of anti-aging related gene of the present invention comprise a special low molecular DNA and a soybean extract, preferably a soybean sprout extract, as active ingredients. These active ingredients have activating actions on the function of the dermal fibroblast and are hence expected to prevent or improve the skin aging such as the reduction of skin firmness and elasticity, wrinkles and sagging.

Abstract: Methods of treating aging related skin changes and of increasing skin thickness with topical administration of N-acyldipeptide derivatives are described. Compositions comprising N-acyldipeptide derivatives, are therapeutically effective for increasing skin thickness, and for treating extrinsic and intrinsic aging and aging related skin changes, such as fine lines, wrinkles, photoaging, hyperpigmentation, laxity, age spots, lentigines, mottled skin, and cellulite.

Abstract: The invention includes methods for reducing or preventing the staining capacity of a compound to a tooth in a mammalian oral cavity, which includes affixing to the tooth surface a degradable film. The film comprises a starch polymer or copolymer that is formed by crosslinking a starch. The film degrades in the oral cavity within about 1 minute to about 70 minutes after affixation. In some embodiments, it may be preferred the crosslinking occurs in the presence of at least one (poly)carboxylic acid. It may be preferred that the starch selected is a retrograde starch, a starch that is chemically or physically modified to be amylase resistant or a starch that is derived naturally but exhibits amylase resistance.

Abstract: This invention relates to a cosmetic composition comprising: (A) a film forming composition that can produce a tack free surface comprising: (I) a hydrosilylation reaction product of: (a) a silicone resin having the formula: (R1R22SiO1/2)w(R1R3SiO2/2)x(R1R2SiO3/2)y(SiO4/2)z wherein R2 is a C1 to C10 hydrocarbon group free of aliphatic unsaturation, R1 is R2 or an alkenyl group, w is from 0.3 to 0.6, x is from 0.0 to 0.2, y is 0, z is from 0.4 to 0.7, w+x+y+z=1.0, and w+z is from 0.85 to 1.

Abstract: A skin cleansing composition has from about 0.05% to about 15%, by weight of the composition, of a plurality of color stable abrasive particles comprising a non-oxide colorant; and an antioxidant selected from the group consisting of tocopherol acetate (Vitamin E Acetate), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium benzotriazolyl butylphenol sulfate, Vitamin C (ascorbic acid) and combinations thereof. The abrasive particles are sustainable. The skin cleansing composition has a pH of <6 or from about 4 to about 6.

Abstract: The present invention relates to a composition containing first oleosomes having a first distribution D50(1) and second oleosomes having a second size distribution D50(2).

Abstract: Compositions comprising one or more of the following extracts: an Euterpe oleracea extract comprising cyanidin 3-glycoside and/or cyanidin 3-rutinoside, an Olea europaea extract comprising oleuropein, a Coffea arabica extract, and/or a Tabebuia impetiginosa extract. The compositions further comprise a micronutrient comprising zinc and vitamin D3. Dietary supplements and hair/body care products comprising the compositions. The compositions are useful for non-medicinal treatment of hair loss and/or nourishment and rejuvenation of hair, skin and nails.

Abstract: The invention relates to the cosmetic use of a Nephelium lappaceum plant extract to reduce the harmful effects of pollution on the skin and/or skin appendages, advantageously the hair, by maintaining and/or increasing the cell viability and/or the ATP synthesis and/or the mitochondrial activity and/or by decreasing the cell senescence and/or the cell damage. The N. lappaceum extract increases the radiance of the complexion of the skin.

Abstract: The inventions relate to cosmetology and are intended to increase a cosmetic effect. A mask comprises a cream-type cosmetic agent and an additional reagent, which are isolated from one another. The agent contains a water-soluble biocompatible polymer which has a mass in the range of 50,000-1,000,000 Da and is capable of entering into a cross-polymerisation reaction. The reagent consists of a substance-electrolyte solution containing multicharged ions. The mass ratio of polymer and substance-electrolyte is from 10:1 to 1:1 respectively. A method involves separately applying to the skin the cream-type agent and then the additional reagent on top.

Abstract: Provided is a cosmetic composition for skin moisturization containing a hydrolyzate extract obtained by adding a protease to the fruit of Cicer arietinum, a Rhododendron chrysanthum leaf extract and a Tricholoma matsutake extract. The cosmetic composition exhibits excellent effects on cell moisturization, intercellular moisturization and skin-barrier moisturization. In addition, the cosmetic composition is harmless to the human body and has excellent stability because it uses natural substances.

Abstract: Described herein is a natural, mineral sunscreen that combines natural oxides with high linoleic acid natural oils. The result is a safe, natural formula for the whole family which is naturally tinted and made from natural ingredients. The composition has an SPF rating of 50+ and provides broad spectrum UVA and UVB protection. The composition contains powerful anti-oxidants, no artificial fragrance(s), is hypoallergenic and is safe for sensitive skin.

Abstract: Alteromonas macleodii Dow02-2 is provided, wherein the Alteromonas macleodii Dow02-2 was deposited at German Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikroorganismen and Zellkulturen, DSMZ) under the accession number DSM33380, and its metabolites comprise 2-hydroxy-3-methylbutyric acid. A method for providing 2-hydroxy-3-methylbutyric acid is also provided, wherein the method comprises isolating the 2-hydroxy-3-methylbutyric acid from metabolites of Alteromonas macleodii Dow02-2 of biologically pure culture. A method for at least one of increasing expression of TGM1 gene, increasing expression of KRT1 gene, increasing expression of KRT10 gene, increasing expression of KRT14 gene, increasing expression of FLG gene, increasing expression of GBA gene, and increasing expression of HAS3 gene is also provided, wherein the method comprises administering to a subject in need thereof an effective amount of 2-hydroxy-3-methylbutyric acid.

Abstract: The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal, pulmonary and ophthalmic disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.

Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.

Abstract: Formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof as the sole active ingredient, a viscosity enhancer, and a buffering agent in an amount to provide a pH of from 5.0 to 7.0 are useful for treating opioid withdrawal syndrome.

Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Abstract: The present invention relates generally to a stable liquid formulation of purified hemopexin comprising: (a) a hemopexin content of at least 50 mg/mL; (b) at least 15 mM phosphate buffer; (c) a pH from 5.8 to 8; and (d) at least 50 mM sodium chloride; and uses thereof.

Abstract: Provided herein are long-acting, non-aqueous pharmaceutically acceptable compositions of active ingredients for subcutaneous injection, in particular analgesics such as buprenorphine.

Abstract: A microprojection array comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a therapeutic agent that is poorly soluble in water or an aqueous solvent.

Abstract: A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

Abstract: In embodiments described herein, an intravaginal device for treating incontinence in women includes one or more treatment modalities. The treatment modalities include: 1) incorporating an antimuscarinic agent into an intravaginal drug delivery device; 2) incorporating an estrogenic agent into an intravaginal drug delivery device, and 3) using a pessary. One or more of these modalities may be used, alone or in combination, to treat incontinence in women.

Abstract: The present disclosure describes pharmaceutical compositions and methods for cleansing the nose, clearing the nose, imparting a cooling sensation in the nose, moisturizing nasal passages, soothing a dry nose, and ameliorating dehydration of the anterior nasal mucosa in humans in need of relief thereof. The compositions herein comprise humectants such as Aloe barbadensis leaf gel, hyaluronic acid, and/or a hyaluronate salt in a buffered and thickened pharmaceutically acceptable carrier. In various aspects, methods for relief comprise nasally administering compositions comprising Aloe barbadensis leaf gel and sodium hyaluronate in a pharmaceutically acceptable carrier to a human in need of relief thereof.

Abstract: A chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the chewing gum has one or more cannabinoids, and wherein the chewing gum generates saliva and delivers at least 10% by weight of the one or more cannabinoids to the oral mucosa during the first 5 minutes of chewing.

Abstract: A chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the chewing gum has one or more cannabinoids, and wherein the chewing gum generates saliva and delivers at least 10% by weight of the one or more cannabinoids to the oral mucosa during the first 5 minutes of chewing.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum being formulated as an extruded chewing gum including water-soluble chewing gum ingredients mixed into water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the one or more elastomer plasticizers includes one or more polyvinyl acetate elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum has one or more cannabinoids.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum includes water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum includes one or more high intensity sweeteners in an amount of 0.01 to 1% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Abstract: The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum including water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the water-soluble chewing gum ingredients include one or more sugar alcohols in an amount of 35-80% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

Abstract: Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.

Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.

Abstract: Coconut oil, coconut oil blends that are high in MCTs such as LouAna® liquid coconut oil, pure MCT oils, Omega-3 oils, cannabidiol (CBD), hemp extract, tree nut oil, macadamia oil, almond oil, cashew oil, avocado oil, docosahexaenoic acid (DHA), fish oil, and/or conjugated linoleic acid (CLA) may be emulsified to create an emulsified oil or blend that may take the form of a creamy shot or a cream substitute. These oils and/or blends may be emulsified using an emulsifier that may be selected from the following: sunflower lecithin, sodium stearoyl lactylate (SSL), acacia gum, beta-cyclodextrin, and combinations of same. By emulsifying these oils/oil blends, a good tasting creamy shot or a cream substitute can be formed.

Abstract: Giant multi-lamellar vesicles (GMVs) comprising lecithin are provided which are at least about 3 ?m in size. Methods for preparing the GMVs, and for preparing large unilamellar vesicles (LUVs) from the GMVs, are provided, as well as methods for encapsulating cargo within the GMVs and LUVs. The present vesicles are useful for the oral delivery of encapsulated cargo.

Abstract: A biodegradable nano-theranostic composite comprising graphene oxide and lipid in the liposomes in the ration of 0.005 to 0.03 characterized in that the graphene oxide is coated as film on the liposome on the inner side and outer side of the liposome. The composite is capable of safely carrying sensitive cargo without premature release and is fluorescent and absorbs in the NIR region and can perform targeted combined chemo and photothermal therapy. The nanotheranostic nanocomposite is designed to collapse and biodegrade after use.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: The present invention relates to a compound having a macromolecular carrier having a plurality of terminal groups, wherein the carbonyl group of serine is linked by a peptide bond or an ester bond directly or via a linker to the terminal groups, a carrier for drug delivery composed of the compound, and a medicament for preventing or treating renal diseases, containing the carrier for drug delivery and a drug bonded to the carrier directly or via a linker or encapsulated therein. According to the present invention, a carrier for drug delivery that is selectively accumulated in kidney in vivo can be provided.

Abstract: Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., ?55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.

Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent iransfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Abstract: The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.

Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Abstract: Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.

Abstract: A delayed release drug formulation includes a core and a coating. The coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release drug formulation is used to target release of a drug from a core to the intestine, particularly the colon.

Abstract: Compositions and methods for systemic delivery of at least one cargo in a vascular plant. Compositions may include at least one cargo delivery particle, having a core and a shell; and at least one cargo disposed on the shell. The core may include at least one micronutrient. The shell may include a coating material. The at least one cargo delivery particle may have a size of less than about 10 nanometers. Methods may include administering an effective amount of the compositions to a plant.

Abstract: The present invention discloses a lipid nanoparticle membrane composition, and the membrane composition comprises a cationic lipid, a neutral phospholipid, cholesterol, Tween, and a polyethylene glycol derivative, with a molar ratio of (25-35):(40-50):(15-25):(1-5):(1-5) in the membrane composition. Also disclosed is a method for preparing a lipid nanoparticle from the lipid nanoparticle membrane composition. The present invention provides a lipid nanoparticle membrane composition that is capable of increasing the stability of the nanoparticle itself, thereby promoting the release of a medicament in tumor tissue and reducing the probability of being degraded.

Abstract: This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.

Abstract: A system for manufacturing an artificial construct suitable for transplantation into a biological organism that includes a two or three three-dimensional preform that is based on the actual two or three-dimensional structure of a native mammalian tissue; and an electrospinning apparatus, wherein the electrospinning apparatus is operative to deposit at least one layer of polymer fibers on the preform to form a polymer scaffold, and wherein the orientation of the fibers in the scaffold relative to one another is substantially parallel.

Abstract: A hemostatic compound is provided. The hemostatic compound comprises molecular sieves and a fiber. The molecular sieves are independently dispersed on a fiber surface of the fiber without agglomeration and directly contact the fiber surface. A first surface of the molecular sieve contacted with the fiber is defined as an inner surface, and a second surface of the molecular sieve uncontacted with the fiber is defined as an outer surface. The molecular sieve forms a growth-matched coupling with the fiber on the inner surface, and the growth-matched coupling refers to that a plurality of molecular sieve microparticles grow to match the fiber surface to form a tightly-coupled coupling interface that matches the fiber surface.